Janux Therapeutics, Inc.

Janux Therapeutics, Inc. (Nasdaq: JANX) is an innovative clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying proprietary platform technologies to address significant unmet medical needs in oncology and autoimmune disease. The company's website is www.januxtherapeutics.com.

The company operates three primary technology platforms: Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM). These platforms are designed to overcome limitations of conventional T cell engager therapeutics, including cytokine release syndrome, on-target healthy tissue toxicity, and short half-lives. The TRACTr platform produces T cell engagers with tumor antigen-binding and CD3 T cell binding domains, while the TRACIr platform produces bispecifics with tumor antigen-binding and costimulatory CD28 binding domains. The ARM platform is engineered to enable controlled T cell activation and expansion followed by contraction for autoimmune disease applications.

Janux's lead clinical candidates include JANX007, a PSMA-targeted TRACTr in Phase 1 clinical trials for metastatic castration-resistant prostate cancer, and JANX008, an EGFR-targeted TRACTr in Phase 1 trials for multiple solid tumors. The company is also advancing JANX011, a CD19-targeted ARM program in Phase 1 development for autoimmune diseases. Additionally, Janux is developing a PSMA x CD28 TRACIr designed to enhance T cell activation and response durability.

Beyond its wholly-owned pipeline, Janux has established strategic collaborations with major pharmaceutical companies. In December 2020, the company entered into a research collaboration with Merck Sharp & Dohme Corp. to develop next-generation TCE immunotherapies, with potential milestone payments up to $500.5 million per target. In January 2026, Janux entered into an exclusive license and collaboration agreement with Bristol Myers Squibb for development and commercialization of a novel tumor-activated therapeutic, with potential milestone payments up to $785 million.

The company's technology platform is designed to be modular and manufacturable using standard mammalian cell expression systems similar to monoclonal antibody production, potentially enabling lower costs of goods compared to cell therapy approaches.